Alnylam Pharmaceuticals (ALNY) financials
Alnylam Pharmaceuticals revenue and earnings by year
Alnylam Pharmaceuticals's revenue was $3.71 billion in the fiscal year to December 31, 2025, up 65.2% from the year before. Net income was $314 million, 8.4% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 62.4% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.71 | 2.25 | 1.83 | 1.04 | 0.84 | 0.49 | 0.22 | 0.07 | 0.09 | 0.05 |
| Revenue growth | 65.2% | 23.0% | 76.2% | 22.9% | 71.3% | 124.3% | 193.4% | -16.7% | 90.7% | — |
| Gross profit | 3.03 | 1.92 | 1.52 | 0.87 | 0.70 | 0.41 | 0.19 | 0.07 | — | — |
| Gross margin | 81.6% | 85.6% | 83.0% | 83.7% | 83.4% | 84.2% | 88.6% | 97.6% | — | — |
| Operating income | 0.50 | -0.18 | -0.28 | -0.79 | -0.71 | -0.83 | -0.94 | -0.81 | -0.50 | -0.42 |
| Operating margin | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% | -168.1% | -427.5% | -1087.6% | -556.2% | -900.3% |
| Net income | 0.31 | -0.28 | -0.44 | -1.13 | -0.85 | -0.86 | -0.89 | -0.76 | -0.49 | -0.41 |
| Net margin | 8.4% | -12.4% | -24.1% | -109.0% | -101.0% | -174.1% | -403.2% | -1016.6% | -545.9% | -869.6% |
| Diluted EPS | $2.33 | -$2.18 | -$3.52 | -$9.30 | -$7.20 | -$7.45 | -$8.15 | -$7.56 | -$5.42 | -$4.78 |
| Free cash flow | 0.47 | -0.04 | 0.04 | -0.61 | -0.72 | -0.69 | -0.42 | -0.69 | -0.49 | -0.37 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open ALNY in Markets.
How Alnylam Pharmaceuticals makes money
Revenue by segment in the quarter to September 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Amvuttra | $1.13B | 77.5% |
| Royalty | $94.7M | 6.5% |
| GIVLAARI | $89.5M | 6.1% |
| Collaborations | $71.5M | 4.9% |
| OXLUMO | $52.5M | 3.6% |
| ONPATTRO | $19.6M | 1.3% |
See also: ALNY valuation and P/E history · ALNY returns
No forecast, no recommendation. This page describes Alnylam Pharmaceuticals from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.